Acorda Therapeutics Inc (ACOR.O) Key Developments | Reuters.com
Edition:
United States

Acorda Therapeutics Inc (ACOR.O)

ACOR.O on Nasdaq

25.31USD
28 Jun 2016
Change (% chg)

$0.83 (+3.39%)
Prev Close
$24.48
Open
$24.75
Day's High
$25.43
Day's Low
$24.75
Volume
424,733
Avg. Vol
736,483
52-wk High
$43.63
52-wk Low
$23.85

Latest Key Developments (Source: Significant Developments)

Acorda Therapeutics says on June 1 entered credit agreement with units - SEC filing
Thursday, 2 Jun 2016 07:53am EDT 

Acorda Therapeutics Inc : On June 1, co, units entered into a credit agreement - SEC filing . Initial availability under facility is approximately $58 million. .Agreement provides company with a three-year senior secured revolving credit facility in maximum amount of $60 million.  Full Article

Biotie Therapies announces final results of subsequent offer period of Acorda Therapeutics tender offer
Monday, 2 May 2016 09:40am EDT 

Biotie Therapies Oyj:Final results of the subsequent offer period of Acorda Therapeutics tender offer for all securities in Biotie.38.4 million shares and 58,121 American Depositary Shares (ADSs) were tendered during subsequent offer period.Together with other equity interests tendered in tender offer during initial offer period, about 97.36 percent of all shares and votes were tendered.  Full Article

Acorda Therapeutics Inc announces results from mid-phase clinical trial of CVT-301
Wednesday, 20 Apr 2016 07:00am EDT 

Acorda Therapeutics Inc:Acorda Announces Results From Phase 2b Clinical Trial Of CVT 301 for treatment of off periods in parkinson's disease published in movement disorders.Participants receiving CVT-301 showed a statistically significant and clinically important reduction in average updrs III score.No serious adverse events reported in drug group, incidence of drug-related adverse events was similar between treatment groups.No adverse events related to cardiovascular or lung function reported.  Full Article

Acorda Therapeutics announces preliminary tender offer results for Biotie Therapies
Monday, 11 Apr 2016 08:55am EDT 

Acorda Therapeutics Inc:Acorda Therapeutics ("Acorda") announces preliminary tender offer results and acceptance of shares, American Depositary Shares ("ADSs"), stock options, share units and warrants in Biotie Therapies Corp tendered in tender offer.Shares and ADSs tendered in the Tender Offer represent about 92.37 pct of all shares and votes in Biotie (excluding treasury shares held by Biotie).  Full Article

Acorda Therapeutics Inc gives FY 2016 AMPYRA net sales guidance
Monday, 11 Jan 2016 07:30am EST 

Acorda Therapeutics Inc:Expects AMPYRA FY 2016 net sales guidance of $475 mln - $485 mln.  Full Article

Acorda Therapeutics Inc raises FY 2015 AMPYRA net revenue guidance
Thursday, 22 Oct 2015 06:00am EDT 

Acorda Therapeutics Inc:Raised FY 2015 guidance for AMPYRA net revenue from $410-$420 million to $420-$430 million.  Full Article

Acorda Therapeutics Inc raises low end of prior FY 2015 AMPYRA net sales guidance
Thursday, 30 Jul 2015 06:00am EDT 

Acorda Therapeutics Inc:Expects FY 2015 AMPYRA net sales guidance in the range of $410-$420 million.  Full Article

Acorda Therapeutics presents data on inhaled levodopa therapy CVT-301
Tuesday, 16 Jun 2015 07:00am EDT 

Acorda Therapeutics:Presents data on inhaled levodopa therapy cvt-301 at international congress of parkinson's disease and movement disorders.Trial showed that patients treated with cvt-301, showed significantly greater improvements in motor function versus placebo.Participants receiving cvt-301 showed statistically significant,clinically important reduction in average updrs III motor score.Says there were no serious adverse events reported in the drug group.Says the incidence of drug-related adverse events was similar between treatment groups.Says pd patients were able to self-administer treatment while in an off state.  Full Article

Acorda Therapeutics Inc reaffirms FY 2015 Ampyra revenue guidance - Conference Call
Tuesday, 2 Jun 2015 07:30pm EDT 

Acorda Therapeutics Inc:Projects FY 2015 net sales of $405 million to $420 million for Ampyra in MS.  Full Article

Acorda Therapeutics Inc reaffirms FY 2015 AMPYRA net revenue outlook
Thursday, 12 Feb 2015 06:00am EST 

Acorda Therapeutics Inc:Expects FY 2015 AMPYRA net revenue of $405-$420 mln.  Full Article

BRIEF-Acorda presents phase 1 data on Migraine drug at 58th annual meeting of American Headache Society

* There were no serious adverse events, dose limiting toxicities, study discontinuations due to adverse events reported for cvt-427